BeyondSpring Announces Pricing of Ordinary Shares
October 25, 2019

NEW YORK, Oct. 25, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global clinical stage biopharmaceutical company focused on the development and commercialization of innovative immuno-oncology cancer therapies, today announced the pricing of its public offering of 1,851,852 ordinary shares at a public offering price of $13.50 per share. The offering was led by Decheng Capital. The gross proceeds from the public offering are expected to be $25.0 million, before deducting underwriting discounts and commissions and other offering expenses. The underwriters have a 30-day option to purchase from the Company up to an additional 277,777 ordinary shares at the public offering price. The Company intends to use the net proceeds of this offering to support continued clinical and pre-clinical development and for general corporate purposes. The offering is expected to close on October 29, 2019, subject to satisfaction of customary closing conditions.

Jefferies and William Blair are acting as joint book-running managers for the offering. Nomura is acting as lead manager for the offering. H.C. Wainwright & Co. is acting as co-manager for the offering.

The offering is being made pursuant to the Company’s existing shelf registration statement, which was filed with the U.S. Securities and Exchange Commission (the “SEC”) on October 15, 2019 and became effective on October 21, 2019. The offering of these securities was made only by means of a prospectus and a related prospectus supplement, which will be filed with the SEC. Copies of the prospectus and prospectus supplement related to this offering may be obtained, when available, from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by calling (877) 821-7388, or by emailing or William Blair, Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, Illinois 60606, or by calling (800) 621-0687, or by emailing

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the shares or any other securities, nor shall there be any sale of such shares or any other securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About BeyondSpring

BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies. BeyondSpring’s lead asset, Plinabulin, is in two Phase 3 global clinical programs, one as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and the other in the prevention of chemotherapy-induced neutropenia (CIN). BeyondSpring has strong R&D capabilities with a robust pipeline in addition to Plinabulin, including three immuno-oncology assets and a drug discovery platform using the ubiquitination degradation pathway. The Company also has a seasoned management team with many years of experience bringing drugs to the global market.

Copyright ? 2011 Decheng Capital LLC. All Rights Reserved.